title: A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA).
abstract: A 35-year-old female with scirrhous stomach cancer (stage IV) was treated with a combination of 5-aminolevulinic acid (ALA), sodium dichloroacetate (DCA), hyperthermotherapy, and immunotherapy as terminal care. The patient survived for one year and seven months, during which her quality of life was markedly improved and she returned to work. The patient was diagnosed with poorly-differentiated adenocarcinoma and progressive signet-ring cell carcinoma, accompanied by left ovarian metastasis, peritoneal dissemination, and right hydronephrosis stage IV, and treated with combination chemotherapy with tegafur-gimeracil-oteracil potassium (TS-1) and docetaxel. Oral ALA and DCA were concomitantly administered at 50 mg each three times a day (150 mg/day, respectively). In addition, hyperthermotherapy using thermotron was concomitantly performed at 2- to 3-week intervals. Cellular immunotherapy with αβ T- and immature dendritic cells was also performed. The disease did not progress for 11 months, her quality of life was markedly improved, and she was able to return to work. However, the signs of enlargement of the ovarian metastatic lesion were noted later, for which chemotherapy with four cycles of second-line paclitaxel and a half dose of irinotecan and cisplatin as third-line treatment were performed. Combination of ALA/DCA, hyperthermotherapy, and cellular immunotherapy may be a low-invasive palliative therapy superior in maintaining quality of life of tumor-bearing terminally ill individuals.
authors.affiliation: Seta Clinic Group, Chiyoda-ku, Tokyo, Japan. m-saito@toushikai.com
authors.forename: Masashi
authors.initials: M
authors.lastname: Saito
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Yano
authors.forename: Takashi
authors.initials: T
authors.lastname: Kamigaki
authors.forename: Shigenori
authors.initials: S
authors.lastname: Goto
mesh_terms: D002293:Adenocarcinoma, Scirrhous / Q000473:pathology / Q000628:therapy*; D000328:Adult; D000622:Aminolevulinic Acid / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D018279:Carcinoma, Signet Ring Cell / Q000473:pathology / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003999:Dichloroacetic Acid / Q000627:therapeutic use; D000077143:Docetaxel; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D000077146:Irinotecan; D010051:Ovarian Neoplasms / Q000556:secondary / Q000628:therapy*; D010094:Oxonic Acid / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000556:secondary / Q000628:therapy*; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011379:Prognosis; D017640:Silicates / Q000008:administration & dosage; D013274:Stomach Neoplasms / Q000473:pathology / Q000628:therapy*; D043823:Taxoids / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage; D014025:Titanium / Q000008:administration & dosage
chemical_list: D004338:Drug Combinations; D017319:Photosensitizing Agents; D017640:Silicates; D043823:Taxoids; C103828:titanium silicide; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid; D000077146:Irinotecan; D000622:Aminolevulinic Acid; D003999:Dichloroacetic Acid; D014025:Titanium; D017239:Paclitaxel; D002945:Cisplatin; D002166:Camptothecin
keywords: ALA; DCA; cellular immunotherapy; hyperthermotherapy; stomach cancer